• 1
    Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489495.
  • 2
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 17331745.
  • 3
    Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651693.
  • 4
    Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 13351340.
  • 5
    Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987; 57: 231236.
  • 6
    Sterneck M, Gunther S, Gerlach J et al. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. J Hepatol 1997; 26: 754764.
  • 7
    Le Bouvier GL. The heterogeneity of Australia antigen. J Infect Dis 1971; 123: 671675.
  • 8
    Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B virus by homology in nucleotide sequence. comparison of surface antigen subtypes. J Gen Virol 1988; 69: 25752583.
  • 9
    Stuyver L, De Gendt S, Van Geyt C et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81 (Part 1): 6774.
  • 10
    Norder H, Courouce AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 1992; 73: 31413145.
  • 11
    Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38: 2434.
  • 12
    Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756– 62.
  • 13
    Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357: 934935.
  • 14
    Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554559.
  • 15
    Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179: 775782.
  • 16
    Ding X, Mizokami M, Yao G et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China Intervirol 2001; 44: 4347.
  • 17
    Orito E, Mizokami M, Sakugawa H et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33: 218223.
  • 18
    Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40: 12071209.
  • 19
    Sumi H, Yokosuka O, Seki N et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37: 1926.
  • 20
    Van Geyt C, Gendt SD, Rombout A et al. A line probe assay for hepatitis B virus genotypes. In: SchinaziRF, SommadossiJ-P, ThomasHC, eds. Therapies for Viral Hepatitis. London: International Medical Press; 1998: pp 139145.
  • 21
    Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325329.
  • 22
    Waters JA, Brown SE, Steward MW, Howard CR, Thomas HC. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 1992; 22: 112.
  • 23
    Waters JA, O'Rourke SM, Richardson SC, Papaevangelou G, Thomas HC. Qualitative analysis of the humoral immune response to the ‘a’ determinant of HBs antigen after inoculation with plasma-derived or recombinant vaccine. J Med Virol 1987; 21: 155160.
  • 24
    Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254263.
  • 25
    Carman WF, Owsianka A, Wallace LA, Dow BC, Mutimer DJ. Antigenic characterization of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. J Hepatol 1999; 31: 195201.
  • 26
    Shields PL, Owsianka A, Carman WF et al. Selection of hepatitis B surface ‘escape’ mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Gut 1999; 45: 306309.
  • 27
    Oon CJ, Lim GK, Ye Z et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13: 699702.
  • 28
    Lee PI, Lee CY, Huang LM, Chen JM, Chang MH. A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants. Vaccine 1995; 13: 16851689.
  • 29
    Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8 (Suppl.): S74S78.
  • 30
    Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995; 345: 10891092.
  • 31
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 11891195.
  • 32
    Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis B- induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841850.
  • 33
    Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001; 8: 237247.
  • 34
    Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B. A cause for concern? Vaccine 1999; 17: 973978.
  • 35
    Hou JL, Wang ZH, Cheng JJ et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001; 34: 10271034.
  • 36
    Weinberger KM, Kreuzpaintner EA, Hottentrager B, Neiffer S, Jilg W. Mutations in the S gene of hepatitis B virus isolates from chronic carriers with anti-HBc as the only serological marker of HBV infection. In: RizzettoM, PurcellRH, GerinJL, VermeG, eds. Viral Hepatitis and Liver Disease. Turin: Minerva Medica; 1997. pp 138143.
  • 37
    Carman WF, Mimms LT. Pre-S/S gene variants. In: RizzettoM, PurcellRH, GerinJL, VermeG, eds. Viral Hepatitis and Liver Disease. Turin: Minerva Medica; 1997. pp 108115.
  • 38
    Ireland JH, O'Donnell B, Basuni AA et al. Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 2000; 31: 11761182.
  • 39
    De Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B. Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998; 29: 669675.
  • 40
    Tillmann HL, Trautwein C, Bock T et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30: 244256.
  • 41
    Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 16701677.
  • 42
    Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology 1997; 40: 337342.
  • 43
    Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000; 31: 219224.
  • 44
    Pillay D, Bartholomeusz A, Cane P, Mutimer D, Schinazi RF, Locarnini S. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int Antivir News 1998; 6: 167169.
  • 45
    Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751757.
  • 46
    Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493499.
  • 47
    Carman WF, Trautwein C, Van Deursen FJ et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489493.
  • 48
    Banerjee K, Guptan RC, Bisht R, Sarin SK, Khandekar P. Identification of a novel surface mutant of hepatitis B virus in a seronegative chronic liver disease patient. Virus Res 1999; 65: 103109.
  • 49
    Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213222.
  • 50
    Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26: 786791.
  • 51
    Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999; 30: 13121317.
  • 52
    Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18421847.
  • 53
    Torresi J, Earnest-Silveira L, Deliyannis G et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293: 305313.
  • 54
    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628633.
  • 55
    Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 17111716.
  • 56
    Niesters HG, Honkoop P, Haagsma EB, De Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177: 13821385.
  • 57
    Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R, Guardia J. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J Hepatol 1998; 28: 510513.
  • 58
    Westland CE, Yang H, Delaney WE, IV et al. Week 48 resistance surveillance in chronic hepatitis B patients enrolled in a phase III clinical study of adefovir dipivoxil. Hepatology 2001; 34: 447A.
  • 59
    Yang H, Westland CE, Delaney WE, IV et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464473.
  • 60
    Torresi J, Earnest-Silveira L, Civitico G et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the ‘fingers’ subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299: 8899.
  • 61
    Bock CT, Tillmann HL, Torresi J et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264273.
  • 62
    Van Der Eijk AA, Niesters HG, Pas SD, De Man RA. Persistence of YMDD variants after withdrawal of Lamivudine. J Hepatol 2002; 36: 304305.
  • 63
    Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 9981002.
  • 64
    Niesters HG, De Man RA, Pas SD, Fries E, Osterhaus AD. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002; 51: 695699.
  • 65
    Lok AS, Zoulim F, Locarnini S et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 37293734.
  • 66
    Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001; 39: 19721974.